Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...